About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, April 29th, 2013

The QualityStocks
Daily Stock List


Unigold, Inc. (UGD.V)

We are reporting on Unigold, Inc. (UGD.V) today, here at the QualityStocks Daily Newsletter.

Unigold, Inc. is a mineral exploration company that lists on the TSX Venture Exchange. The Company principally concentrates on exploring and developing their gold assets in the Dominican Republic. A junior natural resource company, Unigold is a significant mineral property holder in the Dominican Republic. The Company is concentrated within the 75km-wide Cretaceous-age Tireo-formation volcano sedimentary rocks, known for hosting major deposits. Unigold has their corporate headquarters in Toronto, Ontario. The Company received recognition as a TSX Venture 50® company this year.

Unigold' current focus is their 100 percent owned Neita property. They also own or have interest in the Sabeneta property. These properties are all prospective for gold-polymetallic mineralization. Neita is the Company's flagship project. It is one of their four contiguous projects within the Dominican Republic. The Neita concession is approximately 200 linear kilometers northwest of the capital city of Santo Domingo.

For the Neita property, a 5-year exploration license renewal was completed in April of 2012. There exists a gold mineralized zone over 1,100 m of strike and growing at the Candelones and Candelones Extension. There also exists growth opportunity as multiple targets are identified. The Neita property is 22,616 ha.

The Company's objectives are to continue with the 40,000 m drilling program at Candelones Main Zone and Candelones Extension Zone - to complete in 2013. Unigold is working towards an initial NI 43-101 mineral resource at Canelones Main Zone and Candelones Extension Zone. The Company is working to advance metallurgical testing at the Candelones targets. Their objectives also include evaluating and prioritizing the many gold-polymetallic targets defined within the Neita property, as well as focus on new discoveries outside of Candelones on Neita.

Unigold holds 100 percent of the exploration rights, through option agreements, for gold, silver, zinc, copper and all associated minerals on the Sabaneta concessions: El Guanal and El Cerrazo. The Company also holds a sole and exclusive option for commercial mining.

This month, Unigold reported on a proposed strategic investment from IFC, a member of the World Bank Group. IFC is proposing to make a $5,000,000 investment in Unigold. The potential investment will be IFC's first mining sector investment in the Dominican Republic. The investment is subject to the execution of final documentation and the approval by the IFC Board of Directors.

Today, Unigold, Inc. (UGD.V), closed at $0.185, down 2.63%, on 270,500 volume. The stock's 52-week low/high is $0.15/$0.52.

Lone Star Gold, Inc. (LSTG)

FeedBlitz and OTCPicks reported earlier on Lone Star Gold, Inc. (LSTG), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 2007, Lone Star Gold, Inc. is a gold exploration and development company with corporate headquarters in Albuquerque, New Mexico. The Company's acquisition and exploration approach strategically focuses on proven, stable precious metal regions in the United States and Mexico. Lone Star Gold's shares trade on the OTC Bulletin Board. The Company formerly went by the name Keyser Resources, Inc. They changed their name to Lone Star Gold, Inc. in June of 2011.

Currently, Lone Star Gold has a 70 percent Working Interest (WI) in concessions covering 800 hectares in the La Candelaria project in Chihuahua, Mexico. The Company is evaluating these to determine the potential sites that represent the best potential for silver and gold deposits. Property access is through established roadways from the capital city of Chihuahua. Nearby infrastructure includes an airstrip and telecommunication services at the town of Tonachi.

In addition, Lone Star has an undivided 65 percent interest in the San Antonio del Potrero mine tailings project near the city of Hidalgo Del Parral in the state of Chihuahua, Mexico. The Company's due diligence exploration of the San Antonio del Potrero mine tailings project included 10 holes augured to acquire 40 undisturbed samples at depths of 20-25 meters, which yielded positive drilling results. The estimated mine life is 8.3 years at 600 tons per day (tpd) and 6.2 years at 800 tpd.

In early March of this year, Lone Star Gold announced that monies from the Company's $15 million common-stock-purchase investment agreement with Deer Valley Management, LLC have been used to cover all of the Company's operating costs. In addition, Lone Star is currently sending monies from the Agreement to Mexico through their consultant to fund the construction of Lone Star Gold's on-site processing plant at their Tailings Project near the city of Hidalgo Del Parral in the state of Chihuahua.

In March, Lone Star Gold stated that they expect the on-site processing plant to be operational within six months. The plant will use the relatively new benign nitrogen leaching pile process. In Quarter 3 2012, Lone Star's team in Mexico completed a preliminary leach plant development plan. It includes a processing capacity of 1,000 tpd while avoiding the use of cyanide and having minimal environmental impact. Furthermore, leach testing has been completed. It determined that no additional crushing of the tailings material is required and that expected recovery will be between the 88-90 percent range.

Today, Lone Star Gold, Inc. (LSTG), closed at $0.0351, down 7.63%, on 74,900 volume with 11 trades. The average volume for the last 60 days is 315,264 and the stock's 52-week low/high is $0.03/$0.21.

Bioniche Life Sciences, Inc. (BNC.TO)

AllPennyStocks reported previously on Bioniche Life Sciences, Inc. (BNC.TO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1979, Bioniche Life Sciences, Inc. is a research-based, technology-driven, fully integrated Canadian biopharmaceutical company. They concentrate on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets around the world. The Company has three operating divisions: Human Health, Animal Health, and One Health. Bioniche Life Sciences is based in Belleville, Ontario. The Company lists on the Toronto Stock Exchange.

Concerning Human Health, the Company's Bioniche Therapeutics Corp. is responsible for the scientific discovery, pre-clinical research, clinical development, regulatory submissions and commercialization of therapeutic products for use in human medicine. Their research and development (R&D) initiatives focus on the areas of cancer and immunomodulation. Bioniche Therapeutics' uses two platform technologies: mycobacterial cell wall-DNA complex (MCC) and oligonucleotides.

Bioniche Therapeutics' product development candidates include MCC for the treatment of bladder cancer, intraperitoneal cancers (ovarian, colorectal), and metastatic cancers, and a combination of MCC and hyaluronan for the treatment of prostate cancer.

Concerning Animal Health, Bioniche Animal Health is currently the largest Canadian-owned animal health company. Bioniche Animal Health has a large product portfolio. These include reproduction and embryo transfer, immunology, and vaccine products. Folltropin®-V, is their lead product. It is the highest quality and best-selling follicle-stimulating hormone (FSH) in the animal health marketplace globally. Folltropin®-V is used in the embryo transfer industry to induce super ovulation in cattle and sheep.

One Health is the newest division of Bioniche Life Sciences. This division is responsible for researching, developing, manufacturing, and marketing veterinary biopharmaceutical products to address diseases in livestock that may have an effect on human health. The leading One Health initiative is the development and commercialization of a new vaccine for the reduction of E. coli O157:H7 bacteria in cattle.

Earlier this month, Bioniche Life Sciences announced that their E. coli O157 cattle vaccine (Econiche®) is being shipped to Sweden for on-farm studies in some Swedish cattle herds. The Swedish National Veterinary Institute, Swedish Animal Health Service AB and the Swedish Board of Agriculture have collaborated with Bioniche Life Sciences to arrange for the vaccine to be granted Special Treatment Certification for this purpose.

Bioniche Life Sciences, Inc. (BNC.TO), closed Monday at $0.255, down 5.56%, on 191,182 volume. The stock's 52-week low/high is $0.18/$0.69.

Silver Falcon Mining, Inc. (SFMI)

OTCPicks and FeedBlitz reported earlier on Silver Falcon Mining, Inc. (SFMI), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Silver Falcon Mining, Inc. involves in the exploration and development of gold and silver properties in the U.S. The Company is a junior resource production enterprise that has acquired the rights to develop and operate the mines of GoldLand Holdings, Co., on War Eagle Mountain, on the Owyhee Gold Trend of the Silver City Mining District in southern Idaho. Founded in 2007, Silver Falcon Mining has their headquarters in Bradenton, Florida. The Company also has an office in New York City, and a Woodbridge, Ontario office.

In addition, Silver Falcon Mining is 100 percent owner to the historic Sinker Tunnel as well as the four mill sites that intersect the main vein of the Oro fino/Golden Chariot vein. The Sinker Tunnel will allow access to the mountain year round by way of maintained roads. It will also allow Silver Falcon Mining to access possible primary ore reserves via underground mining.

The Company has mineral rights to approximately 1,200 acres on War Eagle Mountain in southern Idaho. Their Diamond Creek Mill is at the foot of War Eagle Mountain; it is serviced by 6.2 miles of paved roads from State Highway 78.

Silver Falcon Mining reported in March that their Diamond Creek Mill Facility's "Denver Flotation Circuit" has exceeded expectations in operational results. They reported that recovery from the ore processed by the new circuit exceeds 90 percent of all precious metals contained. This circuit can reach maximum efficiency at a rate of 10 tons per hour. They also stated that reports on the Sinker Tunnel Gold Project revealed that the Company could extract ore bearing materials.

In addition, in March, Silver Falcon Mining announced that they began once again to deliver precious metal dore bars to the refinery. On March 12, 2013, they added approximately 33 ounces of precious metal to their account at their refiner in Florida. This latest shipment came from concentrate produced before the startup of the floatation circuit at the Company's production facilities in Murphy, Idaho.

Silver Falcon Mining, Inc. (SFMI), closed Monday's trading session at $0.012, down 2.44%, on 778,500 volume with 26 trades. The average volume for the last 60 days is 1,858,584 and the stock's 52-week low/high is $0.0091/$0.0504.

SMACK Sportswear (SMAK)

PennyStocks24 reported this month on SMACK Sportswear (SMAK), Chatter Box Stocks, AwesomeStocks, SquawkBoxStocks, TerrificPennyStocks, StockBomb.com, StockLockandLoad, StockRockandRoll, PennyStockLocks.com did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

With their principal focus on volleyball, SMACK Sportswear is the leading brand of custom designed team and beach active apparel. The Company manufactures their Southern California inspired apparel in their corporate headquarters in Torrance, California. Some of the top pros design and test their product before it is distributed. Incorporated in 2010, Smack Sportswear's shares trade on OTC Bulletin Board.

The Company manufactures and distributes online volleyball apparel for indoor and beach volleyball players. Smack Sportswear is situated only five miles from the epicenter of beach volleyball, the "South Bay". This is where the Company does all their research and development (R&D) with the top professionals in the world.

Smack Sportswear does in house cut/sew, decorating, and they can re-produce virtually anything. The Company has high tech sublimation equipment and direct to garment printers in their warehouse. Their cut/sew staff have been making boardshorts, bikinis and team apparel for more than 20 years. In addition, the Company does contract work for other non-competitive companies.

Recently, Smack Sportswear announced plans to expand their offerings to sports other than volleyball. The Company's intention is to offer team uniforms at first for soccer; beach soccer; rowing/crew; baseball and softball. This new line of uniforms is set to launch in coordination with Smack's Online Uniform Designer early in May. The launch of the Online Uniform Designer will enable customers to create their own unique uniform items very easily. Smack expects to add additional sports in 2014. In addition, the Company will implement an aggressive marketing campaign to attract event and team sponsorships representing each of their new sports.

At the end of March, Smack Sportswear announced the opportunity for loyal Smack customers to become part of the Company's sales and promotion team and grow the brand. With the April launch, the Ambassador Program will be a brand recognition and lead generation program that provides incentives for athletes, fans, coaches, event coordinators, referees, parents and club directors to sell Smack Sportswear products. Ambassadors will help drive potential customers to buy Smack team and beach apparel.

Ambassadors will receive a credit towards Smack gear, and a 3-5 percent commission on any revenues that are realized from their lead generation efforts. Additionally, Ambassadors will receive other benefits such as free tickets to sporting events and the opportunity to come to Southern California and play volleyball with the pros, Jenny Kropp and Whitney Pavlik.

Today, SMACK Sportswear (SMAK), closed at $0.0499, up 23.21%, on 33,875 volume with 10 trades. The average volume for the last 60 days is 364,472 and the stock's 52-week low/high is $0.035/$0.85.

GeneLink Biosciences, Inc. (GNLK)

Top Gun, Darth Trader, and The Stock Psycho reported last week on GeneLink Biosciences, Inc. (GNLK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GeneLink Biosciences, Inc. is a leading biosciences enterprise specializing in consumer genomics. The Company's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. GeneLink uses the latest genetic research information and applied life science technologies to provide products and services that can assist in extending and improving the quality of life. GeneLink Biosciences is based in Orlando, Florida.

The Company's DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured for each individual consumer's wellness requirements. On May 1, 2007, GeneLink Biosciences was granted a U.S. Patent for "Kits and Methods for Assessing Skin Health". This was the third patent to be granted from a portfolio of patent applications filed by the Company in the United States and internationally. GeneLink is the first (and only) company to be granted a patent for a therapeutic skin health regimen linked to DNA-based skin health assessment.

The Company has created an innovative methodology for SNP (single nucleotide polymorphism) based genetic profiling. Patents are issued and pending. GeneLink is marketing and/or licensing these proprietary assessments to companies that manufacture or market to the nutraceutical, personal care and skin care industries. The Company is developing their own proprietary products for sale based on their profiling system.

Their expansion into the bioscience field with their unique genetic profiles helps companies create and deliver customized products - personalized wellness and "quality of life" products tailored to their customer's individual needs - based on the science of genetics. Therefore, this allows the consumer and/or their healthcare provider to ascertain what vitamin/nutritional supplements, skin-care products, and health care or weight loss regimens are indicated for their individual needs.

Earlier this month, GeneLink reported financial results for the fiscal year ended December 31, 2012. In February of 2012, they completed the sale of GeneWize Life Sciences, Inc. to Capsalus Corp. (WELL). The sale and accompanying licensing fees provided $1,165,900 to GeneLink during the fiscal year. GeneLink's Annual net sales decreased from $4,684,577 to $2,136,142.  This decrease is mainly related to the sale of GeneWize and the subsequent conversion from retail to wholesale business model in February 2012.

The operating loss in 2012 was $3,468,997.  The majority of the loss is attributable to the unsupported overhead costs at GeneLink, the establishment of the Company's own manufacturing facility, and the implementation of plans to support GeneLink's expansion into additional channels.  GeneLink also had extraordinary legal expenses related to regulatory compliance.  The net loss for 2012 of $3,051,747 decreased by $748,449 or 20 percent in comparison to the year prior.

GeneLink Biosciences, Inc. (GNLK), closed Monday's trading session at $0.019, down 55.29%, on 2,689,363 volume with 201 trades. The average volume for the last 60 days is 166,520 and the stock's 52-week low/high is $0.0025/$0.1915.

Standard Gold Holdings, Inc. (SDGR)

HEROSTOCKS, Ceocast News, Stock Brain, and FeedBlitz reported earlier on Standard Gold Holdings, Inc. (SDGR), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Incorporated in 1985, Standard Gold Holdings, Inc.'s primary focus is to provide toll milling and custom milling and refining services through specializing in Gold, Silver and Platinum group metals. The Company provides their services mainly to junior mining companies based in the western U.S., Canada, Mexico and Central America. Standard Gold's shares trade on the OTCBB. The Company previously went by the name Standard Gold, Inc. They changed their name to Standard Gold Holdings, Inc., in February of this year.

Toll milling is a process whereby mined material undergoes crushing and is ground into fine particles to ease the extraction of any precious minerals contained in them. The Company's assets include one of the largest private land holdings in Esmeralda County, Nevada; one of the largest tailings holdings; ore dumps; permits, and substantial water rights. The tailing holdings and ore dumps represent potentially substantial precious metal reserves for Standard Gold.

Standard Gold Holdings' services include assaying techniques and professional lab services, and extraction services consisting of laboratory testing, analysis, and modeling. In addition, their services include engineering services consisting of design and commission turnkey facility and operating solutions for individuals, investment groups, or mining companies, as well as refining services.

Customized solutions that compliment a business may include Analytical Protocol Development, Extraction Amenability, Proprietary Milling Operations, Lab Design & Commissioning, Process Engineering Services, Refining, Bonded Warehouse Storage, and Use of Water Rights throughout the western U.S. area.

The Company closed a series of transactions in 2011. They acquired certain assets of Shea Mining & Milling, LLC. These assets include land, buildings, a dormant milling facility, abandoned milling equipment, water permits, mine tailings, mine dumps and the assignment of a note payable, a lease and a contract agreement with permits. They completed the Shea Exchange Agreement to acquire the Shea Mining assets and develop a toll milling services business of precious minerals.

Moreover, Standard Gold is evaluating 6 square miles of piled ore in Manhattan, Nevada that has never undergone processing. With modern technologies, these resources can now undergo processing to recover an estimated range of .036 - .297 Au output, based on previous sampling. This has a projected value of greater than $50 million (USD).

Standard Gold, Holdings Inc. (SDGR), closed Monday at $0.49, even for the day, on 200 volume with 1 trade. The average volume for the last 60 days is 12,489 and the stock's 52-week low/high is $0.1052/$0.545.

Gabriel Resources, Ltd. (GBRRF)

Leeb's Market Forecast reported previously on Gabriel Resources, Ltd. (GBRRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gabriel Resources Ltd. is a resource enterprise focusing on permitting and developing their world class Rosia Montana gold and silver project. The Company is presently at the permitting stage in the process to develop, construct and operate this project. The project is one of the largest undeveloped gold deposits in Europe. Gabriel Resources has their corporate headquarters in Whitehorse, Yukon Territories. The Company's shares trade on the OTC Pink Current Information.

Gabriel Resources owns the Rosia Montana Project via their subsidiary, Rosia Montana Gold Corp. S.A. (RMGC), a Romanian Company in which Gabriel holds an 80.69 percent stake. CNCAF Minvest S.A., a Romanian state-owned mining enterprise, holds the balance. The Company's commitment is to building a new state-of-the-art mining facility to reinvigorate the local and wider economy and to provide an economic basis for sustainable development for the whole region for decades to come.

The Rosia Montana project is one of the most significant gold deposits outside the ownership of a major mining company. It has a Measured
& Indicated Resource of 17.1M oz Au (+1.4M Inferred), 81.1M oz Ag
(Using a cut off grade of 0.4g/t Au). It has a Proven & Probable Reserve of 10.1M oz Au, 47.6M oz Ag (Using US$400/oz Au pit shells).

The Project consists of four open pits, one TMF, two waste stockpile areas, a processing plant as well as other associated facilities. It has a total surface area of 1,257 ha, approximately 7 km in length. The Rosia Montana Project has a 16-year operating mine life.

Permitting for the Project is the core focus of the Company. The permitting progress of the Rosia Montana project relies a great deal on Government approval of the environmental permit (EP) and the issuance, in accordance with due process and Romanian law, of various permits and approvals at local, county and federal levels of government.

Gabriel Resources has additional exploration properties at Bucium Rodu Frasin (Au-Ag) and Bucium Tarnita (Cu-Au). Their second project, the Bucium project, consisting of the Rodu-Frasin (epthermal gold/silver) and Tarnita (porphyry copper-gold) deposits can be considered advanced and early stage exploration projects, respectively.

Gabriel Resources, Ltd. (GBRRF), closed Monday's trading session at $1.69, up 4.97, on 49,300 volume with 90 trades. The average volume for the last 60 days is 21,659 and the stock's 52-week low/high is $1.18/$2.9386.


The QualityStocks
Company Corner


Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0675, up 0.75%, on 1,412,512 volume with 62 trades. The stock’s average daily volume over the past 60 days is 3,190,528, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. reported encouraging preliminary data today out of their Phase 1 dose escalation study designed to evaluate the safety of ADXS-cHER2 in companion dogs with Her2/neu overexpressing canine osteosarcoma, currently underway at the University of Pennsylvania School of Veterinary Medicine. Data from the first two dose groups shows that ADXS-cHER2 at dosages designed to test the upper limits came back with well-tolerated results, precisely the results one should like to see in a study designed to test the maximum tolerated dose and lead investigator, Dr. Nicola Mason, characterized the results as inciting a good deal of eagerness to expand the study.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Reports Encouraging Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study

Advaxis and FusionVax Sign a Memorandum of Understanding for the License of Advaxisí ADXS-HPV in Asia

Advaxis Announces First Patient Dosed in Brown University Sponsored Anal Cancer Study

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.147, off by 6.25%, on 29,500 volume with 5 trades. The stock’s average daily volume over the past 60 days is 16,995, and its 52-week low/high is $0.1568/$1.82.

GlobalWise Investments, Inc. announced signage of a new channel sales partnership today with US-based subsidiary of privately-held Japanese multinational manufacturer of workgroup A4 multifunction printing solutions and provider of managed document services components, Muratec Machinery, Ltd. (founded in 1935), Muratec America, Inc. CEO of GWIV, William "BJ" Santiago, called Muratec America another great channel partner to add to the network and explained that the deal will help GWIV gain more territory on both the public and private side of the equation in the company's strategic focus areas of managed print services and managed services industries.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Enters Into New Channel Sales Partnership With Muratec America

GlobalWise Investments Announces Results for Fiscal Year 2012

GlobalWise Investments, Inc. Completes $3.0 Million Private Placement

Low Carbon Technologies International, Inc. (LWCTF)

The QualityStocks Daily Newsletter would like to spotlight Low Carbon Technologies International, Inc. (LWCTF). Today, The Aristocrat Group Corp. closed trading at $0.154, up 54.00%, on 272,805 volume with 51 trades. The stock’s average daily volume over the past 60 days is 198,697, and its 52-week low/high is $0.02/$1.25.

Low Carbon Technologies International, Inc. reported today that they will move to up-list onto the OTCQX Marketplace after the next quarterly filing, anticipated as being May 31. This move by the ingeniously diversified Clean-tech, Construction, Energy & Energy Efficiency, Environmental, Mining, and Real Estate sectors-based LCTI Low Carbon Technologies is a perfect way to have the exchange validate the company's true enterprise value of around $200M, while increasing investment viability/visibility.

Low Carbon Technologies International, Inc. (LWCTF) is a U.S. based diversified clean-tech holding company focused on the clean-tech, construction, energy, environmental, mining, and real estate sectors. The company’s primary focus is on generating consistent shareholder growth by minimizing expenses and increasing asset values through leveraged acquisitions.

In addition to acquiring profitable companies, LWCTF’s business strategy includes the use of its various technologies in the development of clean-tech projects which are generally located on the company’s real estate assets. As an additional source of revenue, LWCTF also issues sub-licenses to third parties in exchange for a fair amount of project equity and licensing royalties.

To date, LWCTF has acquired 20 clean-tech technologies focused on the following segments: biofuels & chemicals, biomass, energy efficiency, energy storage, environmental mitigation bank, green building, LED lighting, solar, solar desalination, transportation, waste-to-energy, and water. According to a third party appraisal by Marshall & Stevens, the company’s technologies are currently valuated at approximately $142 million.

LWCTF’s management team has accumulated extensive experience in the carbon sector and is well supported by a board of directors comprised of individuals with a wealth of knowledge within the company’s primary sectors of clean-tech operations. The business strategy executed by these professionals has been highly profitable with LWCTF on track to generate upwards of $28 million in EBITDA for fiscal 2013. Disclaimer

Low Carbon Technologies International, Inc. Company Blog

Low Carbon Technologies International, Inc. News:

LCTI Low Carbon Technologies Poised for Up-Listing; Looks Toward OTCQX Market on Heels of Upcoming Quarterly Financial Disclosure

LCTI Low Carbon Technologies YTD Contracts Exceed Fiscal 2012 Year End Revenues

LCTI Low Carbon Technologies YTD Financials Point Toward Increase of Approximately 300% in Fiscal 2013

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.021, up 5.00%, on 649,000 volume with 11 trades. The stock’s average daily volume over the past 60 days is 302,678, and its 52-week low/high is $0.001/$0.12.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Enters Partnership Agreement With KO Entertainment, Inc.

Consorteum Holdings Reaches Strategic Partnership Agreement With Knockout Gaming

Consorteum Holdings Inc. Reaches Funding Agreement With Private Equity Group

Advaxis, Inc. (ADXS) Encouraged by Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma Study

Advaxis, a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases, today told investors of encouraging preliminary data from the Phase 1 dose escalation study evaluating the safety of ADXS-cHER2 in companion dogs with Her2/neu overexpressing canine osteosarcoma being conducted at the University of Pennsylvania School of Veterinary Medicine.

The primary goal of the study is to establish the maximum tolerated dose of ADXS-cHER2. Preliminary data from the first two dose groups (3 dogs each) show that ADXS-cHER2 at either 1 x 10(8) or 5 x 10(8) cfu is well-tolerated. 100% of dogs experienced 1 or more mild (Grade 1) side effects consistent with cytokine release syndrome observed at the time of administration (fever, increased blood pressure, malaise, nausea, and/or vomiting). Early data also suggest that Her2/neu expression in canine osteosarcoma may denote a more aggressive phenotype.

The study is also being used to determine progression-free survival and overall survival. Early results from the first two dose groups (6 dogs) show a significant survival advantage in dogs that received ADXS-cHER2 compared to 6 dogs whose owners elected not to participate in the trial but who were followed for survival (p=0.01).

Dr. Nicola Mason, lead investigator in the Penn canine osteosarcoma study, plans to expand the trial to three additional sites in the United States. ADXS-cHER2 booster vaccinations will be given to evaluate the effects of maintenance immunotherapy.

“The preliminary data from this study are encouraging,” stated Dr. Nicola Mason. “The dogs that have been treated with ADXS-cHER2 are doing very well and although the numbers of vaccinated dogs are small, they do appear to be doing better than dogs with Her2/neu overexpressing tumors that did not receive the vaccine. I am extremely excited to expand this trial, make the vaccine available to more dogs, and determine its therapeutic benefit in dogs with this highly aggressive tumor type.”

“These preliminary findings suggest that the second Advaxis immunotherapy to be evaluated in a clinical setting (in addition to ADXS-HPV) may also improve survival in cancer. Furthermore, a veterinary oncology indication could potentially open an entirely new market for Advaxis Lm-LLO immunotherapies and further validates the versatility of our technology platform and constructs,” commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis.

For more information, visit www.Advaxis.com

GlobalWise Investments, Inc. (GWIV) and Muratec America Ink New Channel Sales Partnership

GlobalWise Investments and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on the design, implementation, and management of cloud-based Enterprise Content Management (“ECM”) systems, today announced the signing of a new channel sales partnership with Muratec America, Inc. (www.muratec.com).

Headquartered in Plano, TX, Muratec America is a U.S. based subsidiary of Muratec Machinery, Ltd., a privately held Japanese multinational corporation founded in 1935. Known throughout North and South America, Muratec America manufactures workgroup A4 (letter/legal) multifunction printing solutions and provides managed document services components. Muratec America has an experienced sales force and over 500 dealers in North America.

“Muratec America represents another fantastic channel partner to expand our growth in both the public and private sectors addressing our strategic focus in the Managed Print Services (MPS) and Managed Services industries. Muratec America already has an established document management practice, and we’re excited to earn their trust as partners. Their technological and domain expertise in document management will most likely expedite our path-to-market and establish our presence in the Managed Print Services and Managed Services industries,” commented William “BJ” Santiago, CEO of GlobalWise. “Muratec has been a proven leader in offering solutions to their distribution channel of 500 dealers throughout North America selling the Muratec line of multifunction printers. Additionally, each Muratec dealer has approximately 2,000 end-user clients who will now be offered our Intellivue™ solution, and we’re excited about this expanded reach to the market.”

“We deeply value our IT managed services and managed document services components with a laser focus on offering best-in-class solutions that enable our dealer network to sell and have a competitive advantage with their clients and trusted relationships,” said Jim D’Emidio, President of Muratec America, Inc. “It was vitally important we found the next generation of an ECM cloud-based provider who understood the mission critical and privacy needs within the copier dealer end-user client community. We were truly impressed with GlobalWise’s unique packaging of their ECM cloud-based solution and their out of the box innovative workflow ‘on-demand’ solution templates that allows our end-user clients to immediately improve on both workflow and paper efficiencies in mission critical business areas. This new ECM model is also easier for the traditional copier dealer sales representatives to sell because it’s not about features and functions but about improving business process optimization for their companies. We’re truly excited about the launch of this relationship with GlobalWise.”

For more information, visit www.globalwiseinvestments.com

International Stem Cell Corp. (ISCO) Gives Lifeline Skin Care the Winning Edge

On the Lifeline Skin Care website (www.LifelineSkinCare.com) it says “Someday, stem cells will change the world. Today, stem cells will change your skin.” Lifeline Skin Care, a subsidiary of International Stem Cell Corp., produces stem cell based skin care products, leveraging technology only available through its association with ISCO. Although the application of stem cells and their regeneration properties to skin rejuvenation has been heavily popularized, Lifeline Skin Care’s offerings are unique.

Specifically, Lifeline stem cell creams are the only products in the world that contain human, non-embryonic stem cell extracts. This is possible because of ISCO’s development of parthenogenesis, the ability to generate true pluripotent stem cells without the use of a fertilized human embryo. It’s a one-of-a-kind technology that not only avoids the ethical issues common to stem cell application, but also results in stem cells that can be immune-matched to millions of people, avoiding the use of immuno-suppression drugs. ISCO scientists are focused on using these stem cells to treat severe diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells.

Lifeline skin care is focused on the application of this technology to skin rejuvenation, combining stem cell biology, nanotechnology, and skin cream formulation technology to produce the highest quality, scientifically tested, and most effective anti-aging products available. The company does not license the brand name, the technology, the stem cell extracts, or proprietary ingredients to any other company. Moreover, revenues from Lifeline Skin Care help fund stem cell research for curing regenerative diseases like diabetes and Parkinson’s Disease.

However, to end users, the real life effectiveness of the product is most important, and is backed up by an independent clinical study showing 63% improved skin tone and brightness, 67% decreased wrinkles appearance, 73% increased skin elasticity, and 93% improved skin hydration.

For additional information, visit www.InternationalStemCell.com

Cardium Therapeutics, Inc. (CXM) Looks to Future with Three-Stage Growth Plan

Cardium Therapeutics is a San Diego based health sciences and regenerative medicine company that has carefully diversified itself with a strategy designed to provide short-term, mid-term, and long-term growth and revenue. In so doing, they have successfully positioned themselves in several markets, much like a rocket with multiple stages timed for continuous acceleration.

Immediate revenue is provided through Cardium’s To Go Brands subsidiary, acquired in 2012, which markets and sells a growing portfolio of over 25 healthy lifestyle products, including nutraceutical powder mixes and supplements designed for both convenience and health of active lifestyle consumers. Their product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements. It’s a big and fast growing market, projected by some to top $200 billion over the next several years, and should continue to provide Cardium with an important source of revenue to support their other developments.

Further down the timeline, but not too far, is Excellagen, Cardium’s FDA-cleared wound treatment gel that has already been proven to significantly aid healing for many types of wounds, including diabetic foot ulcers. The company is in the final commercialization stages for Excellagen, and has been awarded ISO certification to market and sell Excellagen in the U.S. The company has also advanced international registrations. The ease of use and effectiveness of this new treatment, together with the fact that it has broad application potential, bodes well for future revenue.

And finally there is Generx, an important DNA-based angiogenic growth factor therapeutic, designed to actively increase blood flow around the heart for the treatment of heart disease. The product is qualitatively different than traditional drugs for treating heart disease, drugs which only address the pain or future blockages. It is still under development, but Cardium has successfully initiated a phase 3 registration study, and has published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods.

For additional information, visit www.CardiumTHX.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





FOX Penny Stocks



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251